The Medical Letter on Drugs and Therapeutics
New Treatments for Metastatic Prostate Cancer
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved 2 new treatments for castration- resistant (formerly called hormone-refractory) prostate cancer. Sipuleucel-T (Provenge – Dendreon) is the first immunotherapy approved for treatment of prostate cancer. Cabazitaxel (Jevtana – Sanofi-Aventis) is approved for second-line treatment of metastatic castration-resistant prostate cancer previously treated with docetaxel (Taxotere).

CASTRATION-RESISTANT METASTATIC PROSTATE CANCER — Metastatic prostate cancer eventually becomes resistant to hormone treatment. Docetaxel based chemotherapy is the only treatment previously shown to offer a survival benefit for men with metastatic prostate cancer that had become resistant to androgen deprivation therapy. In one study in 1006 men, overall survival was significantly longer with docetaxel plus prednisone (18.9 months) than with mitoxantrone plus prednisone (16.5 months); mitoxantrone ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: New Treatments for Metastatic Prostate Cancer
Article code: 1346b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian